摘要 |
Surprisingly, the present inventors have discovered that expression of TAT-003 protein in human patients is associated with cancer, and that the over-expressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-003 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-003 expression or activity, comprising: contacting a candidate compound with a TAT-003 and detecting the presence or absence of binding between said compound and said TAT-003, or detecting a change in TAT-003 expression or activity. Methods are also included for the identification of compounds that modulate TAT-003 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-003 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.
|
申请人 |
CAPRION PHARMACEUTICALS, INC.;HU, MICHAEL;TSANG, JOHN;JAITLY, NAVDEEP;SWAMY, SAJANI;HAMAIDI, LYES;FILGUEIRA, MARCELO;CHELSKY, DANIEL;LANOIX, JOEL;ENG, KEVIN;THIBAULT, PIERRE;FAUBERT, DENIS;BRUNET, SYLVAIN;OSTERMANN, JOACHIM;BOULOS, MARGUERITE;KEARNEY, PAUL;BUTLER, HEATHER |
发明人 |
HU, MICHAEL;TSANG, JOHN;JAITLY, NAVDEEP;SWAMY, SAJANI;HAMAIDI, LYES;FILGUEIRA, MARCELO;CHELSKY, DANIEL;LANOIX, JOEL;ENG, KEVIN;THIBAULT, PIERRE;FAUBERT, DENIS;BRUNET, SYLVAIN;OSTERMANN, JOACHIM;BOULOS, MARGUERITE;KEARNEY, PAUL;BUTLER, HEATHER |